Skip to main content

Table 1 Information on the healthy donor and patient samples

From: Robust and highly efficient hiPSC generation from patient non-mobilized peripheral blood-derived CD34+ cells using the auto-erasable Sendai virus vector

Healthy donor and patients (hiPSC line) Age (year)/gender No. of cells or blood volume donated No. of purified PBMCs per 1 mL blood sample
Healthy (TkPP2) 33/M 1.0 × 107 cells N.A.
SLE (TkSLE3) 59/F 22 mL 0.5 × 106 cells/mL
SLE (TkSLE4) 50/F 30 mL 0.5 × 106 cells/mL
SLE (TkSLE5) 43/F 30 mL 1.3 × 106 cells/mL
PM (TkSPD3) 65/M 30 mL 0.7 × 106 cells/mL
PM (TkSPD4) 45/F 30 mL 2.4 × 106 cells/mL
PM (TkSPD5) 56/M 30 mL 1.1 × 106 cells/mL
X-CGD (TkSCG3) 18/M 38 mL 0.8 × 106 cells/mL
X-CGD (TkSCG4) 9/F 20 mL 1.2 × 106 cells/mL
PID (TkSPR1) 33/F 30 mL 1.9 × 106 cells/mL
PID (TkSPR2) 30/F 22 mL 1.3 × 106 cells/mL
JIA (TkSCR1) 3/F 23 mL 2.4 × 106 cells/mL
CMS (TkS42–1) 11/F 26 mL 0.7 × 106 cells/mL
MD (TkSmD1) 59/M 40 mL 0.5 × 106 cells/mL
MD (TkSmD3) 32/M 30 mL 1.1 × 106 cells/mL
KCS2 (TkSKCII2) 13/F 22 mL 1.0 × 106 cells/mL
  1. The disease/symptom affecting each individual and the name of the derived human induced pluripotent stem cell (hiPSC) line are listed. The age and gender of each donor are also indicated. The number (No.) of peripheral blood mononuclear cells (PBMCs) and total peripheral blood (PB) volume donated are shown for the purchased healthy donor PBMCs and the patient PBMCs, respectively. The right-hand column shows the number of PBMCs purified from 1 mL of patient PB
  2. SLE systemic lupus erythematosus, PM polymyositis, X-CGD X-linked chronic granulomatous disease, PID primary immunodeficiency, JIA juvenile idiopathic arthritis, CMS congenital malformation syndrome, MD mitochondrial diabetes, KCS2 Kenny-Caffey syndrome type 2, N.A not applicable